Picroside I Composition for Drug-Induced Neutropenia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for drug-induced neutropenia, such as G-CSF and GM-CSF, have adverse effects and there is a need for a safer and more effective therapeutic option derived from natural resources.
Innovation Solution
A pharmaceutical composition comprising purified Picroside I, derived from Picrorhiza kurroa, is developed for treating or preventing neutropenia, with methods for its isolation and formulation into oral and injectable forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If G-CSF or GM-CSF is used to treat neutropenia, then neutrophil count increases and treatment efficacy is improved, but adverse effects such as dyspnea, chest pain, nausea, fever, and injection site reactions occur
Solution Approach 1:
The patent extracts and isolates the active constituent Picroside I from the Picrorhiza kurroa plant material through a multi-step process involving extraction, concentration, and purification steps, obtaining a purified compound free from other plant constituents that may cause adverse effects
Solution Approach 2:
The patent employs a cost-effective extraction methodology using readily available solvents and simple equipment (rotary evaporator, freeze dryer) to produce an affordable alternative to expensive recombinant proteins like G-CSF, making the treatment more accessible
2Reliability
If synthetic drugs are used to treat complex chronic diseases, then treatment efficacy is improved, but associated adverse effects and toxicities increase patients' burden
Solution Approach 1:
The patent changes the chemical parameter of the treatment from synthetic recombinant proteins to naturally occurring plant compounds, specifically isolating Picroside I with defined chemical structure and properties that differ fundamentally from synthetic drug molecules
Solution Approach 2:
The patent utilizes the complex composition of Picrorhiza kurroa roots, which contain multiple bioactive compounds working synergistically, though the final purified product is Picroside I isolated through systematic purification processes
3Object-affected harmful factors
If herbal medicine is used as complementary therapy, then patient burden from adverse effects is reduced, but manufacturing precision and purity control become more challenging
Solution Approach 1:
The patent segments the complex herbal extract into individual purified compounds through systematic separation techniques, isolating Picroside I as a discrete molecular entity with defined purity rather than using crude herbal extracts
Solution Approach 2:
The patent replaces traditional mechanical filtration and separation methods with advanced techniques including rotary evaporation for solvent removal and freeze drying for water elimination, achieving superior purity and concentration control
Data Source
AI summary
The present invention discloses a pharmaceutical composition comprising picroside isolated from Picrorrhize kurroa. The composition contains Picroside I as an active ingredient for treating drug-induced immunopathy such as neutropenia. Methods of isolating Picroside I and Picroside II, and preparing the compositions have also been disclosed herein. The said composition of Picroside I can be a solid oral or an injectable composition of a pre-determined dose. The said composition of Picroside I exhibited reversal of drug-induced immunopathy such as neutropenia through in vivo tests as well as in vitro tests. Therefore, it can be used as a herbal therapeutic agent for treating drug-induced immunopathy such as neutropenia.